Common Stock, par value $0.0001 per share

IMMUNOME, INC.

18702 North Creek Parkway, Bothell, WA, 98011

Rows 11 and 13 of each Reporting Entity's cover page to this Schedule 13D/A set forth the aggregate number of shares of common stock and percentages of the shares of common stock beneficially owned by such Reporting Entity and are incorporated by reference. The percentage set forth in each row 13 is based upon the sum of: (i) 91,710,277 shares of common stock outstanding as of November 3, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 6, 2025 and (ii) 18,625,000 shares of common stock issued in the Issuer's public offering of equity securities that closed on December 18, 2025, as reported in the Issuer's prospectus supplement dated December 16, 2025 filed with the SEC on December 17, 2025.

Rows 7 through 10 of each Reporting Entities' cover page to this Schedule 13D/A set forth the number of shares of common stock as to which such Reporting Entity has the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition and are incorporated by reference.

No transactions with respect to the securities of the Issuer have been effected during the past sixty days by any Reporting Entity. The percentage ownership reported in this amendment reflect an increase in the number of outstanding shares of the Issuer.

No other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the common stock.

The Reporting Entities ceased to be the beneficial owners of more than five percent of the common stock on December 18, 2025.